Limits...
Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G - Curr Clin Pharmacol (2008)

Bottom Line: Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs.The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses.

View Article: PubMed Central - PubMed

Affiliation: Carl Gustav Carus University, Internal Medicine I, Division of Hematology and Oncology, Dresden, Germany.

ABSTRACT

Background: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine--as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine--are frequently used in patients with GBM. Since CYP3A4 is the major isozyme involved in the metabolism of imatinib, we investigated the influence of EIAEDs on imatinib pharmacokinetics (pk).

Methods: GBM patients received 600 mg imatinib p.o./o.d. in combination with 1.0 g HU p.o./o.d..together with either EIAEDs, non-EIAEDs, or no antiepileptic drug (non-AEDs) comedication. Trough plasma levels of imatinib and its active main metabolite N-desmethyl-imatinib (CGP74588) were determined biweekly in these patients, total 543 samples being collected from 224 patients (up to 6 times / patient). All three groups were compared to each other and with historical pharmacokinetic data obtained from patients with chronic myeloid leukemia (CML).

Results: Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%). Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs. Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively. The corresponding mean level for CML patients was 300 ng/ml (CV 50%).

Conclusion: Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs. The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses. In addition these data demonstrate that there is no significant difference in the pharmacokinetics of imatinib between patients with glioblastoma and CML.

Show MeSH

Related in: MedlinePlus

Differences between the mean trough level of imatinib in patients on EIAEDs and without EIAEDs compared to the mean imatinib trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of imatinib and black vertical bars indicate the standard deviation. The red curve represents the calculated mean imatinib plasma decay curve under pseudo steady-state conditions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2748699&req=5

Figure 1: Differences between the mean trough level of imatinib in patients on EIAEDs and without EIAEDs compared to the mean imatinib trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of imatinib and black vertical bars indicate the standard deviation. The red curve represents the calculated mean imatinib plasma decay curve under pseudo steady-state conditions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation.

Mentions: Figs. (1 and 2) compares the mean imatinib and CGP74588 trough level results of group A (non-AED) plus B (non-EIAEDs) to group C (EIAEDs), depicted on the calculated plasma curves from CML patients. They show that the mean trough level of group A plus B fits nearly perfectly to the the CML curves, while for group C significant decreases were observed.


Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.

Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhäuser M, Dresemann G - Curr Clin Pharmacol (2008)

Differences between the mean trough level of imatinib in patients on EIAEDs and without EIAEDs compared to the mean imatinib trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of imatinib and black vertical bars indicate the standard deviation. The red curve represents the calculated mean imatinib plasma decay curve under pseudo steady-state conditions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2748699&req=5

Figure 1: Differences between the mean trough level of imatinib in patients on EIAEDs and without EIAEDs compared to the mean imatinib trough level in CML patients without antiepileptic drugs. Points indicate mean measured trough level of imatinib and black vertical bars indicate the standard deviation. The red curve represents the calculated mean imatinib plasma decay curve under pseudo steady-state conditions from CML patients taking 600mg imatinib o.d.. The grey hutching represents the related standard deviation.
Mentions: Figs. (1 and 2) compares the mean imatinib and CGP74588 trough level results of group A (non-AED) plus B (non-EIAEDs) to group C (EIAEDs), depicted on the calculated plasma curves from CML patients. They show that the mean trough level of group A plus B fits nearly perfectly to the the CML curves, while for group C significant decreases were observed.

Bottom Line: Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs.The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses.

View Article: PubMed Central - PubMed

Affiliation: Carl Gustav Carus University, Internal Medicine I, Division of Hematology and Oncology, Dresden, Germany.

ABSTRACT

Background: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine--as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine--are frequently used in patients with GBM. Since CYP3A4 is the major isozyme involved in the metabolism of imatinib, we investigated the influence of EIAEDs on imatinib pharmacokinetics (pk).

Methods: GBM patients received 600 mg imatinib p.o./o.d. in combination with 1.0 g HU p.o./o.d..together with either EIAEDs, non-EIAEDs, or no antiepileptic drug (non-AEDs) comedication. Trough plasma levels of imatinib and its active main metabolite N-desmethyl-imatinib (CGP74588) were determined biweekly in these patients, total 543 samples being collected from 224 patients (up to 6 times / patient). All three groups were compared to each other and with historical pharmacokinetic data obtained from patients with chronic myeloid leukemia (CML).

Results: Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%). Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs. Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively. The corresponding mean level for CML patients was 300 ng/ml (CV 50%).

Conclusion: Significant decreases of imatinib and CGP74588 trough levels were observed for patients receiving EIAEDs. The EIAED-induced reduction in trough imatinib levels can be avoided by switching to non-EIAEDs comedication or compensated by administering higher imatinib doses. In addition these data demonstrate that there is no significant difference in the pharmacokinetics of imatinib between patients with glioblastoma and CML.

Show MeSH
Related in: MedlinePlus